Sutro Biopharma Revenue 2017-2022 | STRO

Sutro Biopharma revenue from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Sutro Biopharma Annual Revenue
(Millions of US $)
2021 $62
2020 $43
2019 $43
2018 $38
2017 $52
2016 $60
Sutro Biopharma Quarterly Revenue
(Millions of US $)
2022-03-31 $6
2021-12-31 $11
2021-09-30 $9
2021-06-30 $28
2021-03-31 $15
2020-12-31 $8
2020-09-30 $18
2020-06-30 $9
2020-03-31 $7
2019-12-31 $11
2019-09-30 $12
2019-06-30 $11
2019-03-31 $9
2018-12-31 $19
2018-09-30 $8
2018-06-30 $6
2018-03-31 $6
2017-12-31
2017-09-30 $17
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.208B $0.062B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00